Discovery of high quality molecular leads and screening collections for CNS drug targets

Diseases of the central nervous system represent an increasing area of unmet medical need. Despite high levels of investment from the pharmaceutical industry few disease modifying drugs have been discovered with the most common cause of late stage clinical failure being a lack of efficacy. In order...

Full description

Saved in:
Bibliographic Details
Main Author Farnaby, William
Format Dissertation
LanguageEnglish
Published University of Dundee 2019
Online AccessGet more information

Cover

Loading…
Abstract Diseases of the central nervous system represent an increasing area of unmet medical need. Despite high levels of investment from the pharmaceutical industry few disease modifying drugs have been discovered with the most common cause of late stage clinical failure being a lack of efficacy. In order to enable greater understanding of disease mechanisms and the ability to validate specific biological targets for disease intervention, there is a need for medicinal chemists to identify high quality chemical compounds which can reliably probe new therapeutic concepts. Herein, I report three approaches towards this goal. In the first case, a structure based approach allowed the de novo design of a novel class of D-amino acid oxidase (DAAO) inhibitors. This work gave rise to three novel series of DAAO inhibitors, all of which were capable of addressing some or all of the issues that had limited previous attempts to inhibit this high profile CNS target. Furthermore, subsequent optimization by colleagues of chemical leads I discovered and detailed within this thesis, led to the identification of clinical candidate TAK-831. In addition, novel inhibitors for Cholesterol-24-hydroxylase (CH24H) are shown, developed via a property guided approach. The advantages of balancing physicochemical properties throughout lead molecules are demonstrated, giving rise to compounds with in vivo activity in rodent models of spatial learning and memory deficit for this novel drug target. Finally, a strategy for the efficient synthesis of diverse and highly lead-like screening libraries is presented specifically with the objective of providing improved molecular starting points for CNS drug discovery.
AbstractList Diseases of the central nervous system represent an increasing area of unmet medical need. Despite high levels of investment from the pharmaceutical industry few disease modifying drugs have been discovered with the most common cause of late stage clinical failure being a lack of efficacy. In order to enable greater understanding of disease mechanisms and the ability to validate specific biological targets for disease intervention, there is a need for medicinal chemists to identify high quality chemical compounds which can reliably probe new therapeutic concepts. Herein, I report three approaches towards this goal. In the first case, a structure based approach allowed the de novo design of a novel class of D-amino acid oxidase (DAAO) inhibitors. This work gave rise to three novel series of DAAO inhibitors, all of which were capable of addressing some or all of the issues that had limited previous attempts to inhibit this high profile CNS target. Furthermore, subsequent optimization by colleagues of chemical leads I discovered and detailed within this thesis, led to the identification of clinical candidate TAK-831. In addition, novel inhibitors for Cholesterol-24-hydroxylase (CH24H) are shown, developed via a property guided approach. The advantages of balancing physicochemical properties throughout lead molecules are demonstrated, giving rise to compounds with in vivo activity in rodent models of spatial learning and memory deficit for this novel drug target. Finally, a strategy for the efficient synthesis of diverse and highly lead-like screening libraries is presented specifically with the objective of providing improved molecular starting points for CNS drug discovery.
Author Farnaby, William
Author_xml – sequence: 1
  fullname: Farnaby, William
BookMark eNqdizkOwjAQAF1AwfWH_QASckN6DlHRQEFnOc4mXmG8YtdGyu-hyAuoZqTRLM0sc8aFeRxJA39QRuAeIg0R3tUnKiO8OGGoyQsk9J2Czx1oEMRMeYDA6ZcLcVboWeBwvUEndYDiZcCiazPvfVLcTFwZez7dD5dtK1RIY6JWvIwOS2R17GmyNrn6dPum2Vlr_5q-zDlMZw
ContentType Dissertation
DBID AAIPA
LLH
DEWEY 615.1
DatabaseName EThOS: Electronic Theses Online Service (Abstract)
EThOS: Electronic Theses Online Service
DatabaseTitleList
Database_xml – sequence: 1
  dbid: LLH
  name: EThOS: Electronic Theses Online Service
  url: http://ethos.bl.uk/
  sourceTypes: Open Access Repository
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
DissertationAdvisor Ciulli, Alessio
Read, Kevin
DissertationAdvisor_xml – sequence: 1
  fullname: Ciulli, Alessio
– sequence: 2
  fullname: Read, Kevin
DissertationDegree Thesis (Ph.D.)
DissertationSchool University of Dundee
ExternalDocumentID oai_ethos_bl_uk_788022
GroupedDBID AAIPA
LLH
ID FETCH-britishlibrary_ethos_oai_ethos_bl_uk_7880222
IEDL.DBID LLH
IngestDate Tue Apr 04 22:45:40 EDT 2023
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-britishlibrary_ethos_oai_ethos_bl_uk_7880222
Notes 000000047973126X
ParticipantIDs britishlibrary_ethos_oai_ethos_bl_uk_788022
PublicationCentury 2000
PublicationDate 2019
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – year: 2019
  text: 2019
PublicationDecade 2010
PublicationYear 2019
Publisher University of Dundee
Publisher_xml – name: University of Dundee
Score 3.7371235
Snippet Diseases of the central nervous system represent an increasing area of unmet medical need. Despite high levels of investment from the pharmaceutical industry...
SourceID britishlibrary
SourceType Open Access Repository
Title Discovery of high quality molecular leads and screening collections for CNS drug targets
URI http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.788022
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEB7UgqgIWhXfzEF6sSlNsjHxIB5aS5C2FqyQW9hkkyqtGzDNIf_e2Wyk9djbwg4Du8PuvL8BuLO5cFzmKYRLTg5KbDqGl7q2QcaCZ3sKvNJW_c6j8YP_wV4DJ6hHfamY7vIzyzvRQnVRvSnsyX5VSJl3RPZcfMmnYq42NRU5b6SAtqFhkU2ihhcMh_4-HEYaDKgOgqwpi8ERHPTXktzHsJXIJuyO6iR2E1oTDRddtnG66n7K29jCyQpIujyBgPjEqsSyxCxFBSyMugeyxO-_qba4ICHlyKVA-gDIKSVVhEq4VYmVzJGMUuyN31H8FDPUdd_5KViDl2nPN_6fIqxOHCooaL2KFmExD_UNWGewIzOZnAO6KfNs-r2S2OWsyxhPhNkVzBURT0ybmxdwvwHjy42or2CPjIlHHZ64hkZKzye5IY29jG4r2fwCkfWmpg
link.rule.ids 311,780,885,4052,26562
linkProvider British Library Board
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adissertation&rft.genre=dissertation&rft.title=Discovery+of+high+quality+molecular+leads+and+screening+collections+for+CNS+drug+targets&rft.DBID=AAIPA%3BLLH&rft.au=Farnaby%2C+William&rft.date=2019&rft.pub=University+of+Dundee&rft.advisor=Ciulli%2C+Alessio&rft.inst=University+of+Dundee&rft.externalDBID=n%2Fa&rft.externalDocID=oai_ethos_bl_uk_788022